Analyst Reco. Avidity Biosciences, Inc.

Equities

RNA

US05370A1088

Real-time Estimate Cboe BZX Other stock markets 03:36:53 2024-06-10 pm EDT			5-day change	1st Jan Change
27.04 ^USD	+1.67%		-0.30%	+196.46%

Jun. 05	Avidity Biosciences Insider Sold Shares Worth $767,780, According to a Recent SEC Filing	MT
May. 17	Avidity Biosciences Insider Sold Shares Worth $2,121,045, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Avidity Biosciences Insider Sold Shares Worth $767,780, According to a Recent SEC Filing	Jun. 05	MT
Avidity Biosciences Insider Sold Shares Worth $2,121,045, According to a Recent SEC Filing	May. 17	MT
Avidity Biosciences Insider Sold Shares Worth $734,919, According to a Recent SEC Filing	Apr. 04	MT
Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing	Apr. 04	MT
Cantor Fitzgerald Starts Avidity Biosciences With Overweight Rating, $60 Price Target	Mar. 14	MT
Chardan Ups Price Target on Avidity Biosciences to $33 From $23 on Efficacy, Safety DM1 Data, Keeps Buy Rating	Mar. 05	MT
Chardan Trims Price Target on Avidity Biosciences to $23 From $27, Keeps Buy Rating	23-08-09	MT
Evercore ISI Upgrades Avidity Biosciences to Outperform From In Line, Price Target is $20	23-05-22	MT
Wells Fargo Adjusts Price Target on Avidity Biosciences to $50 From $55, Maintains Overweight Rating	23-05-11	MT
Credit Suisse Lowers Avidity Biosciences' PT to $30 From $35 After Announced Partial Clinical Hold on AOC 1001 Trial; Keeps Outperform Rating	23-03-31	MT
Evercore ISI Group Downgrades Avidity Biosciences to In Line From Outperform, Price Target is $20	23-03-31	MT
Wells Fargo Adjusts Price Target on Avidity Biosciences to $55 From $60, Maintains Overweight Rating	23-01-04	MT
Credit Suisse Adjusts Price Target on Avidity Biosciences to $35 From $33 After 'Largely Positive Interim Update' on Drug Trial, Keeps Outperform Rating	22-12-15	MT
Raymond James Adjusts Avidity Biosciences Price Target to $71 From $30, Maintains Strong Buy Rating	22-12-15	MT
Stocks Remain Relatively Flat as Investors Wait for Fed Rate-Hike Move	22-12-14	MT
Credit Suisse Adjusts Avidity Biosciences' Price Target to $33 From $32, Keeps Outperform Rating	22-11-09	MT
Raymond James Adjusts Price Target on Avidity Biosciences to $30 From $29, Maintains Strong Buy Rating	22-11-09	MT
Chardan Research Adjusts Price Target for Avidity Biosciences to $27 From $29, Maintains Buy Rating	22-09-27	MT
Avidity Biosciences Shares Slide on Partial FDA Study Hold	22-09-27	DJ
Avidity Biosciences Shares Rise After Chardan Research Initiates Coverage	22-07-20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Avidity Biosciences, Inc.

Equities

RNA

US05370A1088

Analyst Reco.

Filters